ECSP22011746A - Agentes antipalúdicos - Google Patents

Agentes antipalúdicos

Info

Publication number
ECSP22011746A
ECSP22011746A ECSENADI202211746A ECDI202211746A ECSP22011746A EC SP22011746 A ECSP22011746 A EC SP22011746A EC SENADI202211746 A ECSENADI202211746 A EC SENADI202211746A EC DI202211746 A ECDI202211746 A EC DI202211746A EC SP22011746 A ECSP22011746 A EC SP22011746A
Authority
EC
Ecuador
Prior art keywords
plasmepsin
compounds
treatment
administration
formula
Prior art date
Application number
ECSENADI202211746A
Other languages
English (en)
Inventor
Zhiyu Lei
Bin Hu
Xin Yao
Jennifer K Thompson
Paola Favuzza
Cailing Zhang
Zhuyan Guo
Lera Ruiz Manuel De
Iii Michael J Kelly
Alan F Cowman
Lianyun Zhao
Brad Sleebs
Dongmei Zhan
Tony Triglia
John A Mccauley
Original Assignee
Msd R D China Co Ltd
Merck Sharp & Dohme
Walter & Eliza Hall Inst Medical Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Msd R D China Co Ltd, Merck Sharp & Dohme, Walter & Eliza Hall Inst Medical Res filed Critical Msd R D China Co Ltd
Publication of ECSP22011746A publication Critical patent/ECSP22011746A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona métodos para el tratamiento contra la malaria que comprende la administración de compuestos de la Fórmula (I’): (conforme a figura constante en resumen de memoria técnica) (I’) o una sal de este farmacéuticamente aceptable, a un sujeto que lo necesite, en donde las variables son como se definen en la presente. La invención también proporciona usos de los compuestos de la Fórmula (I), como se define en la presente, para inhibir la actividad de plasmepsina X, plasmepsina IX o plasmepsina X y IX, para el tratamiento contra la infección de Plasmodium, y para el tratamiento contra la malaria. También se proporcionan métodos de tratamiento que comprenden además la administración de uno o más compuestos antipalúdicos.
ECSENADI202211746A 2019-08-15 2022-02-14 Agentes antipalúdicos ECSP22011746A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2019/100781 WO2021026884A1 (en) 2019-08-15 2019-08-15 Antimalarial agents

Publications (1)

Publication Number Publication Date
ECSP22011746A true ECSP22011746A (es) 2023-01-31

Family

ID=74570489

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202211746A ECSP22011746A (es) 2019-08-15 2022-02-14 Agentes antipalúdicos

Country Status (20)

Country Link
US (1) US20220331321A1 (es)
EP (1) EP4013742A4 (es)
JP (1) JP7116859B2 (es)
KR (1) KR20220047312A (es)
CN (1) CN114555564B (es)
AR (1) AR119784A1 (es)
AU (1) AU2020328678B2 (es)
BR (1) BR112022002692A2 (es)
CA (1) CA3147665C (es)
CL (1) CL2022000329A1 (es)
CO (1) CO2022001342A2 (es)
CR (1) CR20220067A (es)
DO (1) DOP2022000037A (es)
EC (1) ECSP22011746A (es)
IL (1) IL290525A (es)
JO (1) JOP20220038A1 (es)
MX (1) MX2022001768A (es)
TW (1) TW202115041A (es)
UA (1) UA128074C2 (es)
WO (2) WO2021026884A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023102747A1 (en) * 2021-12-07 2023-06-15 Merck Sharp & Dohme Llc Antimalarial agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) * 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
UA108363C2 (uk) * 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
EP3380464B1 (en) * 2015-11-25 2020-05-27 UCB Biopharma SRL Iminotetrahydropyrimidinone derivatives as plasmepsin v inhibitors
WO2017142825A2 (en) * 2016-02-18 2017-08-24 Merck Sharp & Dohme Corp. N3-substituted iminopyrimidinones as antimalarial agents
GB201603104D0 (en) * 2016-02-23 2016-04-06 Ucb Biopharma Sprl Therapeutic agents
GB201906804D0 (en) * 2019-05-14 2019-06-26 Ucb Biopharma Sprl Therapeutic agents
WO2021155612A1 (en) * 2020-02-09 2021-08-12 Merck Sharp & Dohme Corp. Antimalarial agents

Also Published As

Publication number Publication date
CN114555564B (zh) 2024-01-30
AR119784A1 (es) 2022-01-12
WO2021027502A1 (en) 2021-02-18
JP7116859B2 (ja) 2022-08-10
DOP2022000037A (es) 2022-06-30
AU2020328678B2 (en) 2023-02-02
EP4013742A1 (en) 2022-06-22
CN114555564A (zh) 2022-05-27
MX2022001768A (es) 2022-06-09
TW202115041A (zh) 2021-04-16
UA128074C2 (uk) 2024-03-27
JP2022534454A (ja) 2022-07-29
CO2022001342A2 (es) 2022-05-20
US20220331321A1 (en) 2022-10-20
IL290525A (en) 2022-04-01
WO2021026884A1 (en) 2021-02-18
CR20220067A (es) 2022-04-20
BR112022002692A2 (pt) 2022-09-27
EP4013742A4 (en) 2023-07-12
JOP20220038A1 (ar) 2023-01-30
CL2022000329A1 (es) 2022-10-07
AU2020328678A1 (en) 2022-03-03
KR20220047312A (ko) 2022-04-15
CA3147665A1 (en) 2021-02-18
CA3147665C (en) 2023-11-28

Similar Documents

Publication Publication Date Title
CO2018010748A2 (es) Agentes antivirales contra la hepatitis b
ECSP18094983A (es) Derivados de pirazol como inhibidores de la calicreína plasmática
CO2018005640A2 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
UY37997A (es) Agentes antivirales contra la hepatitis b
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
PE20151499A1 (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico
WO2017142825A3 (en) N3-substituted iminopyrimidinones as antimalarial agents
UY36207A (es) Inhibidores de la syk
UY36465A (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
DOP2015000169A (es) Compuestos tetracíclicos sustituidos con heterociclo y usos de los mismos para el tratamiento de enfermedades víricas
CO2017000980A2 (es) Compuestos derivados de imidazo[1,2-b]piridazin-2-carboxamida e imidazo[1,2- b]piridazin-2-ilmetanona activos como inhibidores selectivos de la fosfodiesterasa 4a (pde4a)
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
CO2019010559A2 (es) Composiciones y compuestos terapéuticos y métodos para utilizarlos
ECSP22038478A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
CO2021012579A2 (es) Compuestos útiles en la terapia del vih
ECSP19026973A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
ECSP22038509A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
CL2021000329A1 (es) Compuestos útiles en terapia del vih
ECSP22011746A (es) Agentes antipalúdicos
EA201590074A1 (ru) Производное бензодиоксола, способ его получения и его применение
AR067446A1 (es) Un medicamento para tratar higado graso que comprende cilostazol
PE20170430A1 (es) Arilhidrazidas que contienen una fraccion de 2-piridona como agentes antibacterianos selectivos
CY1124339T1 (el) Φαρμακευτικη συνθεση παρατεταμενης αποδεσμευσης η οποια εμπεριεχει ριβαστιγμινη
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer